Answers are grounded in this paper and cite their sources.
Randomized controlled trial examines biomarker-informed therapy guidance, improving clinical outcomes in IBD, suggesting enhanced treatment strategies.
Background Anti-Tumour Necrosis Factor (TNF) therapies are a cornerstone in the treatment of inflammatory bowel disease (IBD), yet therapy responses vary widely among patients. Despite extensive biomarker discovery efforts, the clinical utility of defined molecular marker sets remains largely unexplored. The GUIDE-IBD trial was designed to assess the efficacy of biomarker-informed therapy decisions by comparing guidance through a molecular therapy board to standard medical care in active IBD patients initiating anti-TNF therapy. Methods A randomized controlled trial was conducted at three German university hospitals (DRKS00032030). Adults with Crohn’s disease (CD) or ulcerative colitis (UC) with an indication for first-time infliximab therapy were randomized to “molecular medicine care” (MMC) or “best care” (BC), stratified by diagnosis, centre and baseline corticosteroid use. Molecular assessments (at baseline, weeks 2, 6, 14, and 26), including mRNA-based biomarkers from blood and biopsies, were processed real-time and provided as a principal-component analysis along with pharmacometrics modelling. Molecular reports were provided for the MMC group at weeks 2, 14, 26 and 52; BC data were not disclosed. Primary outcome was Comprehensive Disease Control (CDC) at week 52 (clinical remission (CDAI <150, Partial Mayo <2), endoscopic remission (SES-CD ≤4 [≤2 in ileal CD], MES ≤1), and biochemical normalization (CRP <5 mg/L, faecal calprotectin <250 mg/g)). A logistic regression model with adjustment for the covariates used for randomization and gender was used to test superiority of the MMC arm compared to BC and to estimate odds ratios and adjusted endpoint proportions. Results 103 patients were randomized between 4th February 2021 and 18th January 2024 and included in the modified intention-to-treat analysis. At week 52, CDC was significantly more frequent in the MMC group (22 of 48 patients, adjusted proportion 43%) compared to the BC group (14 of 55, adjusted proportion 23%), with an odds ratio of 2.53 (95%-CI: 1.09-5.86, p = 0.031). All secondary outcomes were in favour of the MMC arm, such as steroid free remission, clinical remission and endoscopic remission, while difference between both arms was only significant for steroid free remission. More therapy switches occurred in the MMC arm (48% vs. 29%) and dose adjustments were also more frequent in the MMC arm (48% vs. 35%). Conclusion Biomarker-informed guidance significantly improved therapy outcomes, with a higher proportion of patients achieving CDC compared to standard “best care” in the context of anti-TNF therapy. These findings support the integration of molecular medicine approaches in therapy boards to optimize treatment strategies in IBD. References: 1.Mishra N, Aden K, Blase JI, et al; SYSCID Consortium. Longitudinal multi-omics analysis identifies early blood-based predictors of anti-TNF therapy response in inflammatory bowel disease. Genome Med. 2022;14(1):110. doi:10.1186/s13073-022-01112-z 2.Schräpel C, Kovar L, Selzer D, et al. External model performance evaluation of twelve infliximab population pharmacokinetic models in patients with inflammatory bowel disease. Pharmaceutics. 2021;13(9):1368. doi:10.3390/pharmaceutics13091368 3.Schreiber S, Aden K, Tran F, Rosenstiel P. Rise of precision medicine: can it deliver on its promise in IBD? Gut. Published online October 6, 2025. doi:10.1136/gutjnl-2023-330000 4.Schreiber S, Feagan BG, Louis E, et al. Distinct trajectories of symptomatic response in ulcerative colitis during filgotinib therapy: a post hoc analysis from the SELECTION study. United European Gastroenterol J. 2024;12(9):1243-1255. doi:10.1002/ueg2.12686 Conflict of interest: Tran, Florian: Grant: Sanofi/Regeneron Personal Fees/Speaker’s fees: Abbvie, Bristol-Myers-Squibb, Celltrion Healthcare, Dr Falk Pharma, Eli Lilly, Ferring Pharmaceuticals, J&J, Sanofi, Takeda Consulting honoraria: AbbVie, J&J, Takeda Aden, Konrad: Personal Fees: Lecture fee: Takeda, Janssen, Lilly, Abbvie Consulting fee: Takeda, Jannsen, Lilly, Guidepoint P. Bernardes, Joana: I have no conflict of interest to declare Imm, Charlot: No conflicts Kovar, Christina: C.
No takes yet. Share an insight, caveat, or question.
Tran et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: